Details

Autor(en) / Beteiligte

• McCarter, Robert J
• Hempe, James M
• Gomez, Ricardo
• Chalew, Stuart A

Titel

Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes

Ist Teil von

• Diabetes care, 2004-06, Vol.27 (6), p.1259-1264

Ort / Verlag

United States: American Diabetes Association

Erscheinungsjahr

2004

Quelle

MEDLINE

Beschreibungen/Notizen

• Biological Variation in HbA 1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes Robert J. McCarter , SCD 1 2 3 , James M. Hempe , PHD 4 5 , Ricardo Gomez , MD 4 and Stuart A. Chalew , MD 4 5 1 Biostatistics and Informatics Unit, Children’s Research Institute, The Children’s National Medical Center, Washington, DC 2 Department of Pediatrics, George Washington University School of Medicine, Washington, DC 3 Department of Epidemiology and Biostatistics, George Washington University School of Medicine, Washington, DC 4 Department of Pediatrics, Louisiana State University Heath Sciences Center, New Orleans, Louisiana 5 Research Institute for Children, Children’s Hospital of New Orleans, Louisiana Address correspondence and reprint requests to Dr. Stuart Chalew, Endocrinology/Diabetes, Children’s Hospital of New Orleans, 200 Henry Clay Ave., New Orleans, LA 70118. E-mail: schale{at}lsuhsc.edu Abstract OBJECTIVE —We hypothesized that biological variation in HbA 1c , distinct from variation attributable to mean blood glucose (MBG), would predict risk for microvascular complications in the Diabetes Control and Complications Trial (DCCT). RESEARCH DESIGN AND METHODS —A longitudinal multiple regression model was developed from MBG and HbA 1c measured in the 1,441 DCCT participants at quarterly visits. A hemoglobin glycation index (HGI = observed HbA 1c - predicted HbA 1c ) was calculated for each visit to assess biological variation based on the directional deviation of observed HbA 1c from that predicted by MBG in the model. The population was subdivided by thirds into high-, moderate-, and low-HGI groups based on mean participant HGI during the study. Cox proportional hazard analysis compared risk for development or progression of retinopathy and nephropathy between HGI groups controlled for MBG, age, treatment group, strata, and duration of diabetes. RESULTS —Likelihood ratio and t tests on HGI rejected the assumption that HbA 1c levels were determined by MBG alone. At 7 years’ follow-up, patients in the high-HGI group (higher-than-predicted HbA 1c ) had three times greater risk of retinopathy (30 vs. 9%, P < 0.001) and six times greater risk of nephropathy (6 vs. 1%, P < 0.001) compared with the low-HGI group. CONCLUSIONS —Between-individual biological variation in HbA 1c , which is distinct from that attributable to MBG, was evident among type 1 diabetic patients in the DCCT and was a strong predictor of risk for diabetes complications. Identification of the processes responsible for biological variation in HbA 1c could lead to novel therapies to augment treatments directed at lowering blood glucose levels and preventing diabetes complications. DCCT, Diabetes Control and Complications Trial HGI, hemoglobin glycation index MBG, mean blood glucose UAER, urinary albumin excretion rate Footnotes Accepted February 21, 2004. Received November 24, 2003. DIABETES CARE